David McGirr Joins LifeCell Board of Directors
12 Noviembre 2007 - 7:00AM
PR Newswire (US)
BRANCHBURG, N.J., Nov. 12 /PRNewswire-FirstCall/ -- LifeCell
Corporation (NASDAQ:LIFC) announced today that David W. J. McGirr
joined the Company's Board of Directors and also will serve as
Chairman of the Audit Committee. Mr. McGirr is Senior Vice
President and CFO at Cubist Pharmaceuticals, Inc. (NASDAQ:CBST) and
has served in his current position since November 2002. He also
served as Treasurer of Cubist from November 2002 until January
2003. From 1999 to 2002, Mr. McGirr was the President and Chief
Operating Officer of hippo, inc., an internet technology,
venture-financed company. Mr. McGirr served as a member of hippo's
Board of Directors from 1999 to 2003. From 1996 to 1999, he was the
President of GAB Robins North America, Inc., a risk management
company, serving also as Chief Executive Officer from 1995 to 1996.
Mr. McGirr was a private equity investor from 1995 to 1996. From
1978 to 1995, Mr. McGirr served in various positions within the
S.G. Warburg Group, ultimately as Chief Financial Officer, Chief
Administrative Officer and Managing Director of S.G. Warburg &
Co., Inc., a position he held from 1992 to 1995. Mr. McGirr
received a B.Sc. in Civil Engineering from the University of
Glasgow and received an M.B.A. from the Wharton School at the
University of Pennsylvania. "I believe that David's diversified
experience and successful track record make him a valuable addition
to our Board," said Paul G. Thomas, President and Chief Executive
Officer of LifeCell. The Company also announced that Michael Cahr
is leaving the LifeCell Board after having been involved with the
company for nearly twenty years and serving as a director for more
than fifteen years. Michael is leaving the board to devote full
time to his role as a Partner at Focus Equity Partners, an Oak
Brook, Illinois based private equity firm. Mr. Cahr joined the
Board in 1991 and during his tenure served as Chairman of both the
Compensation and Audit Committees. "Michael played a major role in
LifeCell's early stages of development and we want to recognize and
thank him for his invaluable contributions as a board member over
the years," Mr. Thomas noted. About LifeCell LifeCell develops and
markets innovative biologically-based products in the emerging
field of regenerative medicine for use in reconstructive,
orthopedic and urogynecologic surgical procedures. LifeCell's
current marketed products include: AlloDerm(R), for plastic
reconstructive, general surgical, burn and periodontal procedures;
Cymetra(R), a particulate form of AlloDerm(R) suitable for
injection; GraftJacket(R), for orthopedic applications and lower
extremity wounds; AlloCraft(R)DBM, for bone grafting procedures;
and Repliform(R), for urogynecologic surgical procedures. The
Company's research and development initiatives include programs
designed to extend the use of its current marketed regenerative
tissue matrix products into new surgical applications as well as
expanding its product line in the rapidly growing biosurgery
market. LifeCell maintains a website at http://www.lifecell.com/.
DATASOURCE: LifeCell Corporation CONTACT: Steven T. Sobieski, Chief
Financial Officer for LifeCell Corporation, +1-908-947-1106, ; or
Kevin McGrath of Cameron Associates for LifeCell Corporation,
+1-212-245-8800, Web site: http://www.lifecell.com/
Copyright
Lifecell Corp (MM) (NASDAQ:LIFC)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Lifecell Corp (MM) (NASDAQ:LIFC)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Lifecell Corp (MM) (NASDAQ): 0 recent articles
Más de Lifecell (MM) Artículos de Noticias